Polymorphic OCT1: a valid biomarker, but for which drugs?

Pharmacogenomics. 2013 Dec;14(16):1933-6. doi: 10.2217/pgs.13.189.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Pharmacological*
  • Cations
  • Humans
  • Metformin / chemistry
  • Metformin / therapeutic use
  • Morphine / chemistry
  • Morphine / therapeutic use
  • Niacinamide / analogs & derivatives
  • Niacinamide / chemistry
  • Niacinamide / therapeutic use
  • Organic Cation Transporter 1 / antagonists & inhibitors
  • Organic Cation Transporter 1 / chemistry
  • Organic Cation Transporter 1 / genetics*
  • Pharmacogenetics*
  • Phenylurea Compounds / chemistry
  • Phenylurea Compounds / therapeutic use
  • Sorafenib

Substances

  • Biomarkers, Pharmacological
  • Cations
  • Organic Cation Transporter 1
  • Phenylurea Compounds
  • Niacinamide
  • Morphine
  • Metformin
  • Sorafenib